SEARCH

SEARCH BY CITATION

References

  • 1
    Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31(Suppl. 1): 1724.
  • 2
    De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995; 345: 4135.
  • 3
    Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C. a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 46372.
  • 4
    Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 4753.
  • 5
    Benvegnu L & Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci 1996; 41(Suppl.): S4955.
  • 6
    Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32(Suppl. 1): 22537.
  • 7
    Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 10657.DOI: 10.1038/2053
  • 8
    Maringhini A, Cottone M, Sciarrino E, et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci 1988; 33: 4751.
  • 9
    Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C. patients with cirrhosis. Hepatology 1997; 26: S12832.
  • 10
    Renault PF & Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9: 2737.
  • 11
    Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 10515.
  • 12
    International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 15359.DOI: 10.1016/s0140-6736(98)07236-5
  • 13
    Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 949.
  • 14
    Valla DC, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 18705.
  • 15
    Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 1999; 131: 696701.
  • 16
    Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 7548.
  • 17
    Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27: 2015.
  • 18
    Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 1417.
  • 19
    Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83: 9019.DOI: 10.1002/(sici)1097-0142(19980901)83:5<901::aid-cncr15>3.0.co;2-z
  • 20
    Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 143540.
  • 21
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 17481.
  • 22
    Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30: 6539.
  • 23
    EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 31(Suppl. 1): 38.
  • 24
    Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 1999; 31(Suppl. 1): 2533.
  • 25
    Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394402.
  • 26
    Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C. A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 112430.
  • 27
    Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999; 85: 194350.DOI: 10.1002/(sici)1097-0142(19990501)85:9<1943::aid-cncr10>3.0.co;2-f
  • 28
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 142632.DOI: 10.1016/s0140-6736(98)07124-4
  • 29
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 30
    Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999; 117: 40813.
  • 31
    Poynard T, Moussali J, Ratziu V, Regimbeau C, Opolon P. Effects of interferon therapy in ‘non responder’ patients with chronic hepatitis C. J Hepatol 1999; 31(Suppl. 1): 17883.
  • 32
    Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 548.
  • 33
    Hu KQ & Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 13116.